Dr. Mikhail Blagosklonny – A Scientist of Oncology and Biogerontology

Dr. Mikhail Blagosklonny has been studying aging and oncology for about twenty years. He is a Russian scientist who is currently based in the United States of America.Dr. Mikhail Blagosklonny has been conducting his research at the Roswell Park Cancer Institute for the last few years. The institution is located in New York City. Before that, Dr. Mikhail Blagosklonny used to teach medicine at the New York Medical College. In 2009, he received a position at his current work place and became a professor of oncology. After the New York Medical College and before the Roswell Park Cancer Institute, Dr. Mikhail Blagosklonny was a member of the institution Ordway Research Institute. It is located in Albany, New York City. He was working as senior scientists from 2002 up until 2009. Dr. Mikhail Blagosklonny had been looking for an institution that would provide him with freedom for his research and study in oncology and aging which are his primary scientific fields.

The alma mater of Dr. Mikhail Blagosklonny is the First Pavlov State Medical University of St. Peterburg. He has studied Internal medicine and majored with an M. D. He also did cardiology and experimental medicine which he graduated with a Ph. D. The institution of the First Pavlov State Medical University is one of the most highly esteemed medical universities in the vast country.Over the course of his scientific career, Dr. Mikhail Blagosklonny became an active proponent of the drug Rapamycin as a possible drug against aging. The medication is a treatment for cancer. The drug of Rapamycin uses TOR signaling. Dr. Mikhail Blagosklonny has been very passionate about the medication in terms of longevity use.Throughout his career, scientific research has not been the only thing that has captivated the dedication of Dr. Mikhail Blagosklonny. He is also an editor as well as chief editor.

Over the past handful of years, Dr. Mikhail Blagosklonny has been one of the editors of the journals titled Aging and Cell Cycle – both are about biogerontology or the science of aging. Dr. Mikhail Blagosklonny is editor in chief of Oncotarget which is publishing research in oncology but has expanded its topics of publication since a few years ago. Along with that, Dr. Mikhail Blagosklonny has also been acting as associate editor of the journal of Cancer Biology and Therapy. He is on the editorial board of the journal Cell Death and Differentiation.Dr. Mikhail Blagosklonny has been doing a lot of writing as well. Over the course of his career, a lot of the research that Dr. Mikhail Blagosklonny has been documented in his papers. Up to date, Dr. Mikhail Blagosklonny is an author of more than 250 articles. Most of them have been published in other journals which are also reviewed by peers.As a scientist, Dr. Mikhail Blagosklonny has been researching all things Oncology and aging. He has been focused on discovering ways to decrease the death of cells. Biogerontology studies aging mechanisms in the human body and Dr. Mikhail Blagosklonny has done many analyses on them to discover a revolutionary way to slow down aging.

Omar Boraie Pledges $1.5 Million to aid Fight Cancer

Omar Boraie is the fast to pledge his family charity donation of 1.5 million US Dollar in setting up one out of the eighteen research chairs to be established at Rutgers Cancer Institute in New Jersey. An anonymous financial aider has granted the institution a challenge grant of 27 million US Dollar to assist in setting 18 research chairs. Each chair requires 3 million allocation. Omar gift has been used to set one Chair in Genomic Science. The chair has the highest standard of higher education, and the institution has guaranteed its success and prosperity.

The groundbreaking chair is named after the financier, Mr. Sam Boraie, and will be used to carry out tumor research and treatment of cancer at genetical scale. The science behind the treatment is using genomic sequencing, an approach commonly only used in exceptional circumstances of cancer treatment, where cancer subtypes are grouped based on their characteristic similarity and genetical differences. The classification then simplifies research for each class. Even President Obama, during State of the Union Address, certified and expressed his optimism in the launch of precision medicine initiative as a solution to cancer therapy.

Commending the initiative, Mr. Omar said in an NJ Biz interview that his family contribution to the project is an inspiration, influence and a call for everyone out there to join hands to surpass the laid target so that the connoisseurs at the Institute could find a long-lasting solution to cancer

Mr. Omar is a chemist and has interest and good will for cancer research and has stayed at the cutting edge of transforming New Brunswick. His generosity was also highly applauded and valued by the Institute Director, Mr. Robert S. DiPaola.

The Omar Boraie Chair of Genomic Science will be held by the experienced oncologist and a top academician in the field, Dr. Ganesan Shridar, who also gave a brief biological understanding of the genetics of cancer before honouring the appointment, and assuring his total involvement and dedication to propel the innovation.

Lastly to those who are not conversant with Rutgers Cancer Institute, the institution is found in New Jersey and is dedicated to researching on cancer treatment. It has various hospitals in the state where it disseminates its innovations and also take part in cancer patient treatment and care. To read more visit prnewswire.com.

(this article is recapped from; http://newswise.com/articles/omar-boraie-chair-in-genomic-science-established-at-rutgers-cancer-institute)

http://magazine.rutgers.edu/insights/seeing-the-future